Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Palatin Techs
(AMEX:PTN)
Intraday
$1.70
-0.03
[-1.73%]
After-Hours
$1.70
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.70
-0.03
[-1.73%]
At close: Apr 24
$1.70
0
[0.00%]
After Hours: 5:13PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Palatin Techs Stock (AMEX:PTN)
Palatin Techs Stock (AMEX: PTN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 12, 2024
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Avi Kapoor
-
Apr 12, 2024, 8:36AM
Monday, April 08, 2024
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Vandana Singh
-
Apr 8, 2024, 10:02AM
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Benzinga Newsdesk
-
Apr 8, 2024, 7:31AM
Wednesday, February 28, 2024
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avi Kapoor
-
Feb 28, 2024, 2:02PM
HC Wainwright & Co. Maintains Buy on Palatin Techs, Adjusts Price Target To $17
Benzinga Newsdesk
-
Feb 28, 2024, 1:16PM
Palatin Technologies shares are trading lower after the company announced results for its PL9643 MELODY-1 Pivotal Phase 3 clinical trial in patients with dry eye disease did not meet co-primary sign endpoints and secondary sign endpoints.
Benzinga Newsdesk
-
Feb 28, 2024, 12:49PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Feb 28, 2024, 12:31PM
Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets
Vandana Singh
-
Feb 28, 2024, 10:57AM
Dow Dips 200 Points; TJX Posts Upbeat Sales
Avi Kapoor
-
Feb 28, 2024, 10:12AM
Palatin Technologies Shared Resumed Trade
Benzinga Newsdesk
-
Feb 28, 2024, 9:44AM
Palatin Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Down -40.8%
Benzinga Newsdesk
-
Feb 28, 2024, 9:36AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Feb 28, 2024, 8:06AM
Palatin Reports Results Of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial In Patients With Dry Eye Disease; On An Intent-To-Treat Analysis, Co-primary Sign Endpoint And Secondary Sign Endpoints Not Met
Benzinga Newsdesk
-
Feb 28, 2024, 7:34AM
Thursday, February 15, 2024
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Benzinga Newsdesk
-
Feb 15, 2024, 12:39PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Feb 15, 2024, 12:31PM
Palatin Techs Reported Wednesday Q2 2024 GAAP EPS $(0.56) Misses $(0.20) Estimate, Sales $2.03M Miss $6.30M Estimate
Benzinga Newsdesk
-
Feb 15, 2024, 7:35AM
Earnings Scheduled For February 15, 2024
Benzinga Insights
-
Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Earnings Preview: Palatin Techs
Benzinga Insights
-
Feb 14, 2024, 3:02PM
Monday, February 05, 2024
Palatin Technologies Announced Database Lock For Its PL9643 Melody-1 Phase 3 Trial Evaluating The Safety And Efficacy Of PL9643 Versus Vehicle For Dry Eye Disease; Top-line Results Expected In February
Benzinga Newsdesk
-
Feb 5, 2024, 7:32AM
Tuesday, January 30, 2024
Palatin Announces $10M Registered Direct Offering of 1.8M Shares at $5.46/Share
Benzinga Newsdesk
-
Jan 30, 2024, 8:07AM
Monday, January 08, 2024
Palatin Provides Corporate Update And Highlights Strategic Priorities For Calendar Year 2024; Completed Asset Sale To Cosette Pharmaceuticals For Up To $171M; $12M Upfront Plus Sales-Based Milestones Of Up To $159M
Benzinga Newsdesk
-
Jan 8, 2024, 10:34AM
Wednesday, January 03, 2024
Cosette Pharmaceuticals Acquires Vyleesi (Bremelanotide Injection) from Palatin Technologies; Deal Terms Were Not Disclosed
Benzinga Newsdesk
-
Jan 3, 2024, 8:04AM
Wednesday, December 27, 2023
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Dec 27, 2023, 12:31PM
Wednesday, December 20, 2023
Palatin Technologies Announced The Sale Of Vyleesi To Cosette Pharmaceuticals For Up To $171M, Vyleesi Is FDA-Approved For Premenopausal Women With Acquired, Generalized Hypoactive Sexual Desire Disorder
Benzinga Newsdesk
-
Dec 20, 2023, 7:42AM
Monday, December 18, 2023
Palatin Receives Notice Of Acceptance Of The Listing Standards Compliance Plan From NYSE American
Benzinga Newsdesk
-
Dec 18, 2023, 4:15PM
Friday, December 15, 2023
Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Dec 15, 2023, 8:17AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Dec 15, 2023, 8:08AM
Monday, December 04, 2023
Palatin Technologies Filed For Up To 2,476,416 Shares Of Common Stock By Selling Shareholders
Charles Gross
-
Dec 4, 2023, 5:04PM
Tuesday, November 14, 2023
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Recap: Palatin Techs Q1 Earnings
Benzinga Insights
-
Nov 14, 2023, 7:40AM
Palatin Q1 Net Product Revenue $2.106M, Up From $869.65K YoY
Benzinga Newsdesk
-
Nov 14, 2023, 7:32AM
Monday, November 13, 2023
Palatin Techs's Earnings Outlook
Benzinga Insights
-
Nov 13, 2023, 1:01PM
Monday, October 23, 2023
Palatin Technologies Announces $5M Registered Direct Offering
Benzinga Newsdesk
-
Oct 23, 2023, 7:39AM
Thursday, October 19, 2023
Palatin Sees Prelim. Q1 Gross Product Revenue $4.6M, Up 11% QoQ Ad Up 100% YoY
Benzinga Newsdesk
-
Oct 19, 2023, 7:35AM
Wednesday, October 18, 2023
Palatin Technologies Plans Initiating Clinical Study Of Melanocortin 4 Receptor Agonist + GLP-1 In Obese Patients; Reports Preclinical Data Showing Synergistic Weight Loss
Benzinga Newsdesk
-
Oct 18, 2023, 7:37AM
Friday, October 13, 2023
Palatin Receives Notice Of Non-Compliance From Nyse American
Benzinga Newsdesk
-
Oct 13, 2023, 4:16PM
Thursday, September 28, 2023
Palatin's Cash, Cash Equivalents And Marketable Securities Were Approximately $11.M Sufficient To Fund Currently Anticipated Operating Expenses Through Calendar Year 2023
Benzinga Newsdesk
-
Sep 28, 2023, 7:34AM
Palatin Techs Q4 EPS $(0.91) Misses $(0.56) Estimate, Sales $1.76M Beat $1.37M Estimate
Benzinga Newsdesk
-
Sep 28, 2023, 7:33AM
Earnings Scheduled For September 28, 2023
Benzinga Insights
-
Sep 28, 2023, 6:59AM
Wednesday, September 27, 2023
Earnings Outlook For Palatin Techs
Benzinga Insights
-
Sep 27, 2023, 10:01AM
Tuesday, September 19, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 19, 2023, 12:50PM
Thursday, September 07, 2023
Palatin Completes Enrollment In Phase 3 MELODY-1 Study Of PL9643 For Treatment Of Patients With Dry Eye Disease
Benzinga Newsdesk
-
Sep 7, 2023, 7:33AM
Thursday, August 10, 2023
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Benzinga Newsdesk
-
Aug 10, 2023, 8:05AM
Tuesday, August 08, 2023
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 12:26PM
Palatin Technologies Says Vyleesi Licensee Fosun Pharma Reports First Commercial Sale In China
Benzinga Newsdesk
-
Aug 8, 2023, 7:34AM
Monday, August 07, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Aug 7, 2023, 1:30PM
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Aug 7, 2023, 1:28PM
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $70 Price Target
Benzinga Newsdesk
-
Aug 7, 2023, 12:28PM
Palatin Announces Partnership To Make Vyleesi Available To Patients On UpScriptHealth's Telehealth Platform
Benzinga Newsdesk
-
Aug 7, 2023, 7:34AM
Friday, July 21, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Jul 21, 2023, 1:24PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch